nex 18 for the
treatment of mDS (MYELODYSPLASTIC SYNDROME)

WHAT IS MDS?

Myelodysplastic Syndrome (MDS) is a cluster of aggressive, prolonged and increasingly prevalent blood cancers that cause a wide range of grueling symptoms such as nausea, dizziness and shortness of breath to bleeding disorders and frequent infections

Forty percent of MDS patients are categorized as high or very high risk and receive a survival prognosis of around 2 years (1). MDS is often referred to as “pre-leukemia” – a third of patients go on to develop acute myeloid leukemia (AML).

PREVALENT
MDS is more common among the elderly and is growing increasingly prevalent due to a rising elderly population, combined with a slowly improving treatment regime ⁽³⁾ over recent decades. In 2019, there were 238,000 cases worldwide, forecast to increase to 313,500 cases by 2028  ⁽⁴⁾.

NEX-18 will reduce
seven daily injections to
one monthly 

Treatment with NEX-18 will offer a single monthly injection – replacing the seven daily doses per treatment cycle currently needed.

Today azacitidine suffers from an inconvenient dosage regimen, where daily subcutaneous injections are given for seven days in each monthly cycle (i.e. seven injections per month). In reality, patients are often treated in a technically off-label 5-2 regimen from Monday to Friday, and Monday and Tuesday of the following week, or receive a modified higher dose during five consecutive days, to fit hospital outpatient hours. This regimen is not only inconvenient for patients, but it is also costly for providers compared to a single monthly injection of NEX-18. NEX-18 would consequently fill a real unmet medical need for patients as well as relatives and health care providers.

from 7 injections a month

to 1 injection a month

Controlled release,
RESULTS IN smarter care

Azacitidine’s side effects are, according to patient testimony ⁽⁵⁾, typically most severe at the beginning of each treatment cycle and during the patient’s first two treatment cycles.